GAA has published the following statement on AquAdvantage Salmon:
On Nov. 19, the U.S. Food and Drug Administration approved the production, sale and consumption of AquaBounty’s AquAdvantage® Salmon. AquAdvantage Salmon may be raised only at two land-based, closed-containment facilities in Canada and Panama. The facilities would be eligible to apply for Best Aquaculture Practices (BAP) third-party certification if they choose to do so. The BAP standards do not allow grow-out of genetically modified salmon in cages where escapement is a possibility. “We’re pleased that the FDA has reviewed AquAdvantage Salmon extremely thoroughly and decided to go forward with approval based on sound science. Ultimately, the marketplace will dictate the acceptance of AquAdvantage Salmon,” said Global Aquaculture Alliance Executive Director Wally Stevens.
The Global Aquaculture Advocate’s 10 takeaways from the FDA’s AquAdvantage® Salmon decision: http://advocate.gaalliance.org/gm-salmon-and-the-fda-10-takeaways/?utm_source=hootsuite